CUB domain containing protein 1Genealiases: CD318 · SIMA135 · TRASK
Q-omics provides the consensus-scored CDCP1 profile across patient tissues and cancer cell-line models. CDCP1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, CDCP1 is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, CDCP1 RNA expression shows 18,563 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUAD, and GBM as cancer lineages where CDCP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDCP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDCP1 survival associations across molecular data types. CDCP1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDCP1 RNA expression–survival associations across cancer types. High CDCP1 expression shows unfavorable associations in LUAD, KIRC, LGG, PAAD and MESO, but favorable associations in COAD. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for CDCP1 RNA expression.
This table summarizes CDCP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in LUAD for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for CDCP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDCP1 shows higher tumor expression in LUAD, BLCA, LUSC, UCEC, STAD and HNSC. The LUAD box plot shows higher CDCP1 RNA expression in tumor versus normal tissue (log2 FC = +1.455, t-test p < 0.001).
This table shows molecular features associated with CDCP1 in patient tissues and cancer cell lines. In patient samples, CDCP1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CDCP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
